151 related articles for article (PubMed ID: 36544385)
1. Reduced D
Weiss AR; Bertoglio D; Liguore WA; Brandon K; Templon J; Link J; McBride JL
Mov Disord; 2023 Jan; 38(1):143-147. PubMed ID: 36544385
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
Delva A; Van Laere K; Vandenberghe W
Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
[TBL] [Abstract][Full Text] [Related]
3. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [
Grachev ID; Meyer PM; Becker GA; Bronzel M; Marsteller D; Pastino G; Voges O; Rabinovich L; Knebel H; Zientek F; Rullmann M; Sattler B; Patt M; Gerhards T; Strauss M; Kluge A; Brust P; Savola JM; Gordon MF; Geva M; Hesse S; Barthel H; Hayden MR; Sabri O
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1103-1115. PubMed ID: 32995944
[TBL] [Abstract][Full Text] [Related]
4. Reduced D2/D3 Receptor Binding of Extrastriatal and Striatal Regions in Temporal Lobe Epilepsy.
Bernedo Paredes VE; Buchholz HG; Gartenschläger M; Breimhorst M; Schreckenberger M; Werhahn KJ
PLoS One; 2015; 10(11):e0141098. PubMed ID: 26544593
[TBL] [Abstract][Full Text] [Related]
5. Improved synthesis of [
Huhtala T; Poutiainen P; Rytkönen J; Lehtimäki K; Parkkari T; Kasanen I; Airaksinen AJ; Koivula T; Sweeney P; Kontkanen O; Wityak J; Dominiquez C; Park LC
EJNMMI Radiopharm Chem; 2019 Aug; 4(1):20. PubMed ID: 31659519
[TBL] [Abstract][Full Text] [Related]
6. [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases.
Döbrössy MD; Braun F; Klein S; Garcia J; Langen KJ; Weber WA; Nikkhah G; Meyer PT
Nucl Med Biol; 2012 Oct; 39(7):1077-80. PubMed ID: 22591915
[TBL] [Abstract][Full Text] [Related]
7. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
[TBL] [Abstract][Full Text] [Related]
8. Positive association between cerebral grey matter metabolism and dopamine D
Mitelman SA; Buchsbaum MS; Christian BT; Merrill BM; Buchsbaum BR; Mukherjee J; Lehrer DS
World J Biol Psychiatry; 2020 Jun; 21(5):368-382. PubMed ID: 31552783
[No Abstract] [Full Text] [Related]
9. Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy: an [18F]fallypride PET study.
Werhahn KJ; Landvogt C; Klimpe S; Buchholz HG; Yakushev I; Siessmeier T; Müller-Forell W; Piel M; Rösch F; Glaser M; Schreckenberger M; Bartenstein P
Epilepsia; 2006 Aug; 47(8):1392-6. PubMed ID: 16922886
[TBL] [Abstract][Full Text] [Related]
10. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
[TBL] [Abstract][Full Text] [Related]
11. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.
Häggkvist J; Tóth M; Tari L; Varnäs K; Svedberg M; Forsberg A; Nag S; Dominguez C; Munoz-Sanjuan I; Bard J; Wityak J; Varrone A; Halldin C; Mrzljak L
J Nucl Med; 2017 Apr; 58(4):617-622. PubMed ID: 27856625
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using
Bertoglio D; Weiss AR; Liguore W; Martin LD; Hobbs T; Templon J; Srinivasan S; Dominguez C; Munoz-Sanjuan I; Khetarpal V; Verhaeghe J; Staelens S; Link J; Liu L; Bard JA; McBride JL
J Nucl Med; 2023 Oct; 64(10):1581-1587. PubMed ID: 37591545
[TBL] [Abstract][Full Text] [Related]
14. Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism.
Casteels C; Martinez E; Bormans G; Camon L; de Vera N; Baekelandt V; Planas AM; Van Laere K
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2354-63. PubMed ID: 20680268
[TBL] [Abstract][Full Text] [Related]
15. Normal caudate glucose metabolism in persons at risk for Huntington's disease.
Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R
Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844
[TBL] [Abstract][Full Text] [Related]
16. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.
Araujo DM; Cherry SR; Tatsukawa KJ; Toyokuni T; Kornblum HI
Exp Neurol; 2000 Dec; 166(2):287-97. PubMed ID: 11085894
[TBL] [Abstract][Full Text] [Related]
17. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia.
Buchsbaum MS; Christian BT; Lehrer DS; Narayanan TK; Shi B; Mantil J; Kemether E; Oakes TR; Mukherjee J
Schizophr Res; 2006 Jul; 85(1-3):232-44. PubMed ID: 16713185
[TBL] [Abstract][Full Text] [Related]
18. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
20. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol.
Vandehey NT; Moirano JM; Converse AK; Holden JE; Mukherjee J; Murali D; Nickles RJ; Davidson RJ; Schneider ML; Christian BT
J Cereb Blood Flow Metab; 2010 May; 30(5):994-1007. PubMed ID: 20040928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
